Clinical Trials Logo
  1. Home
  2. Non-small Cell Lung Cancer NSCLC
  3. NCT05863819

A Real World Study of Mobocertinib in Adults With Lung Cancer in China (MEANING) — MEANING-20  

Non-small Cell Lung Cancer (NSCLC) Clinical Trial

Official title:
Effectiveness and Safety of Mobocertinib in Patients With EGFR Exon 20 Insertion NSCLC in Routine Clinical Practice in China: A Prospective, Single-arm, Multicenter, Observational Study

Clinical Trial Summary

The main aim of this study is to learn about the time from start of mobocertinib to end of treatment with mobocertinib for any reason in Chinese adults with lung cancer who carry a certain gene mutation (epidermial growth factor receptor - EGFR exon 20 insertion mutation) during normal clinical practice. Participants will be treated with mobocertinib as per their normal routine. Data for this study will be collected from the available medical records of a participant.

Clinical Trial Description

This is a non-interventional, prospective, observational study of participants with EGFR ex20ins positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who received mobocertinib in China's routine clinical practice setting. The primary objective of this study is to assess the real-world time-to-treatment discontinuation (rwTTD) of mobocertinib in study participants. The study will enroll approximately 120 participants. Participants will be enrolled in the following cohort: • Mobocertinib Participants will be treated with mobocertinib as per their normal routine treatment. Data for this study will be collected from the available medical records of a participant every 3 months until the end of treatment and follow up (up to 18 months). This multi-center trial will be conducted in China. The overall duration of the study will be approximately 3 years. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05863819
Study type Observational
Source Takeda
Contact
Status Withdrawn
Phase
Start date March 30, 2024
Completion date February 1, 2027
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT06040541 - Study of RMC-9805 in Participants With KRASG12D-Mutant Solid Tumors Phase 1
Recruiting NCT05107674 - A Study of NX-1607 in Adults With Advanced Malignancies Phase 1
Active, not recruiting NCT03667820 - Study of Osimertinib and Stereotactic Ablative Radiation (SABR) in EGFR Mutant NSCLC Phase 2
Completed NCT02025114 - Selumetinib in Combination With Gefitinib in NSCLC Patients Phase 1/Phase 2
Recruiting NCT01994057 - A Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients Treatment
Completed NCT01438307 - Phase II Study of Cabazitaxel-XRP6258 in Advanced Non-Small Cell Lung Cancer Phase 2
Completed NCT01193959 - Pemetrexed in Advanced Non-small Cell Lung Cancer
Recruiting NCT01028729 - A Study of Endostar Combined With Chemotherapy Followed by Endostar Maintenance Therapy to Treat Advanced Non-small Cell Lung Cancer (NSCLC) Phase 4
Completed NCT00770588 - Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (Stage IIIB/IV) Non Small Cell Lung Cancer (NSCLC) Phase 4
Active, not recruiting NCT05462717 - Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors Phase 1
Completed NCT01951157 - A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients Phase 2
Recruiting NCT01964157 - An Open-label, Multicenter, Phase II Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement Phase 2
Active, not recruiting NCT04026412 - A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery Phase 3
Recruiting NCT05585320 - A Phase 1/2a Study of IMM-1-104 in Participants With Previously Treated, RAS-Mutant, Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT03260491 - HER3-DXd in Metastatic or Unresectable Non-Small Cell Lung Cancer Phase 1
Completed NCT05207423 - A Chart Review Study of Adults With Advanced NSCLC
Terminated NCT02608528 - Serial [18F]Fluorodeoxyglucose ([18F]FDG )PET/CT as a Biomarker of Therapeutic Response in Anti-PD1/PDL1 Therapy
Completed NCT01463423 - Individualized Lung Tumor Stereotactic Ablative Radiotherapy (iSABR) N/A
Recruiting NCT02927340 - A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions Phase 2
Recruiting NCT02521051 - Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer Phase 1/Phase 2